{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:52:55Z","timestamp":1791373975615,"version":"4.3.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["NU58DP007156"],"award-info":[{"award-number":["NU58DP007156"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005002","name":"California Department of Public Health","doi-asserted-by":"publisher","award":["California Health and Safety Code Section 103885"],"award-info":[{"award-number":["California Health and Safety Code Section 103885"]}],"id":[{"id":"10.13039\/100005002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["HHSN261201800009I"],"award-info":[{"award-number":["HHSN261201800009I"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jtha.2026.09.005","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T15:17:05Z","timestamp":1789226225000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence, risk factors, and outcomes of thromboembolism in patients with melanoma receiving immune checkpoint inhibitors, chemotherapy, or targeted therapy: a Surveillance, Epidemiology, and End Results-Medicare analysis"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3429-4468","authenticated-orcid":false,"given":"Tamara A.","family":"Sussman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siran M.","family":"Koroukian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok A.","family":"Khorana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2026.09.005_bib1","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1002\/cncr.23062","article-title":"Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients","volume":"110","author":"Khorana","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jtha.2026.09.005_bib2","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2026.09.005_bib3","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJM200012213432504","article-title":"Prognosis of cancers associated with venous thromboembolism","volume":"343","author":"S\u00f8rensen","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.09.005_bib4","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1634\/theoncologist.2013-0226","article-title":"Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis","volume":"18","author":"Lyman","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.jtha.2026.09.005_bib5","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1182\/blood-2018-06-860874","article-title":"Arterial thromboembolic events preceding the diagnosis of cancer in older persons","volume":"133","author":"Navi","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.09.005_bib6","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.3324\/haematol.2018.192419","article-title":"Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer","volume":"103","author":"Grilz","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2026.09.005_bib7","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1182\/blood.2020007878","article-title":"Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy","volume":"137","author":"Moik","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.09.005_bib8","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.09.005_bib9","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.09.005_bib10","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1182\/blood-2010-02-270116","article-title":"Prediction of venous thromboembolism in cancer patients","volume":"116","author":"Ay","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.09.005_bib11","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1160\/TH12-04-0241","article-title":"Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials","volume":"108","author":"Thaler","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.09.005_bib12","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/jth.14630","article-title":"Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors","volume":"18","author":"Gervaso","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.09.005_bib13","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/annonc\/mdr592","article-title":"Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials","volume":"23","author":"Petrelli","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtha.2026.09.005_bib14","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1001\/jama.2008.656","article-title":"Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis","volume":"300","author":"Nalluri","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2026.09.005_bib15","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006278","article-title":"Cardiovascular adverse events in patients with cancer treated with Bevacizumab: a meta-analysis of more than 20 000 patients","volume":"6","author":"Totzeck","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jtha.2026.09.005_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001719","article-title":"Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival","volume":"9","author":"Sussman","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtha.2026.09.005_bib17","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1158\/1055-9965.EPI-13-1138","article-title":"Venous thromboembolism and cancer risk among elderly adults in the United States","volume":"23","author":"Marks","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jtha.2026.09.005_bib18","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtha.2026.09.005_bib19","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtha.2026.09.005_bib21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"key":"10.1016\/j.jtha.2026.09.005_bib22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ahj.2004.02.013","article-title":"Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records","volume":"148","author":"Kiyota","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.jtha.2026.09.005_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227653","article-title":"Validity of cerebrovascular ICD-9-CM codes in healthcare administrative databases. The Umbria data-value project","volume":"15","author":"Orso","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2026.09.005_bib24","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1161\/01.STR.0000032240.28636.BD","article-title":"Validating administrative data in stroke research","volume":"33","author":"Tirschwell","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2026.09.005_bib25","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1056\/NEJM200012143432403","article-title":"Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty","volume":"343","author":"White","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.09.005_bib26","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1161\/01.STR.0000174293.17959.a1","article-title":"Coding of stroke and stroke risk factors using International Classification of Diseases, revisions 9 and 10","volume":"36","author":"Kokotailo","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2026.09.005_bib27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1161\/CIRCULATIONAHA.113.003543","article-title":"Twenty-year analysis of trends in the incidence and in-hospital mortality for lower-extremity arterial thromboembolism","volume":"128","author":"Korabathina","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2026.09.005_bib28","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"key":"10.1016\/j.jtha.2026.09.005_bib29","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.jtha.2026.09.005_bib30","author":"Greifer"},{"key":"10.1016\/j.jtha.2026.09.005_bib31","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1541-0420.2010.01493.x","article-title":"Competing risks regression for stratified data","volume":"67","author":"Zhou","year":"2011","journal-title":"Biometrics"},{"key":"10.1016\/j.jtha.2026.09.005_bib32","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2021.09.010","article-title":"Immune checkpoint inhibitors for cancer and venous thromboembolic events","volume":"158","author":"Gong","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtha.2026.09.005_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010761","article-title":"Immune checkpoint inhibitor-associated risk for venous thromboembolism: a comprehensive analysis","volume":"13","author":"Sussman","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtha.2026.09.005_bib34","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.medj.2021.02.002","article-title":"Increased incidence of venous thromboembolism with cancer immunotherapy","volume":"2","author":"Roopkumar","year":"2021","journal-title":"Med"},{"key":"10.1016\/j.jtha.2026.09.005_bib35","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/ajh.26954","article-title":"Venous thromboembolism risk in cancer patients receiving first-line immune checkpoint inhibitor versus chemotherapy","volume":"98","author":"Li","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2026.09.005_bib36","article-title":"Thromboembolism in patients with melanoma receiving immune checkpoint inhibitors: incidence and risk factors","volume":"27","author":"van Dorst","year":"2025","journal-title":"Immunooncol Technol"},{"key":"10.1016\/j.jtha.2026.09.005_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2024.109243","article-title":"Thromboembolic events associated with immune checkpoint inhibitors in cancer patients: a Bayesian network meta-analysis","volume":"246","author":"Lin","year":"2025","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.09.005_bib38","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1073\/pnas.83.12.4533","article-title":"Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1","volume":"83","author":"Bevilacqua","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2026.09.005_bib39","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.beha.2008.12.009","article-title":"Procoagulant mechanisms in tumour cells","volume":"22","author":"Falanga","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.jtha.2026.09.005_bib40","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3390\/jcm8060762","article-title":"Disorder of coagulation-fibrinolysis system: an emerging toxicity of anti-PD-1\/PD-L1 monoclonal antibodies","volume":"8","author":"Sato","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtha.2026.09.005_bib41","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.smim.2016.10.010","article-title":"Blood coagulation in immunothrombosis\u2014at the frontline of intravascular immunity","volume":"28","author":"Gaertner","year":"2016","journal-title":"Semin Immunol"},{"key":"10.1016\/j.jtha.2026.09.005_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006072","article-title":"Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer","volume":"11","author":"Khorana","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtha.2026.09.005_bib43","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.thromres.2009.12.023","article-title":"Venous thromboembolism and prognosis in cancer","volume":"125","author":"Khorana","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.09.005_bib44","article-title":"Impact of venous thromboembolism on the mortality in patients with cancer: a population-based cohort study","volume":"34","author":"S\u00f8rensen","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jtha.2026.09.005_bib45","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaw8405","article-title":"Myeloid cell-synthesized coagulation factor X dampens antitumor immunity","volume":"4","author":"Graf","year":"2019","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jtha.2026.09.005_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022446","article-title":"Characterization of the MDSC proteome associated with metastatic murine mammary tumors using label-free mass spectrometry and shotgun proteomics","volume":"6","author":"Boutt\u00e9","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2026.09.005_bib47","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1158\/0008-5472.CAN-18-3206","article-title":"Thrombin signaling promotes pancreatic adenocarcinoma through PAR-1\u2013dependent immune evasion","volume":"79","author":"Yang","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtha.2026.09.005_bib48","doi-asserted-by":"crossref","first-page":"11832","DOI":"10.1073\/pnas.89.24.11832","article-title":"Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis","volume":"89","author":"Mueller","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2026.09.005_bib49","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.09.005_bib50","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1758834015616934","article-title":"Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy","volume":"8","author":"Eroglu","year":"2016","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jtha.2026.09.005_bib51","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626005659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626005659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:15:37Z","timestamp":1791371737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783626005659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":50,"alternative-id":["S1538783626005659"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2026.09.005","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence, risk factors, and outcomes of thromboembolism in patients with melanoma receiving immune checkpoint inhibitors, chemotherapy, or targeted therapy: a Surveillance, Epidemiology, and End Results-Medicare analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2026.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}